Anti-VEGF Injections for Diabetic Retinopathy Linked to Systemic Adverse Events
Patients with type 2 diabetes who received intravitreal anti-vascular…
Browsing Tag
AntiVEGF
Ashvattha Therapeutics Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2…
<!-- Name:DistributionId Value:8825608 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
No Visual Acuity Benefit With Early Anti-VEGF for Diabetic Retinopathy
Longer-term follow-up of a randomized trial confirmed that prophylactic anti-VEGF therapy…
Most Patients With Neovascular Eye Disease Prefer Anti-VEGF Implant
Reduced treatment burden for neovascular age-related macular degeneration met with overwhelming…
Anti-VEGF Market Size is projected to reach USD 13.54 Billion by 2030, growing at a…
New York, United States, July 21, 2022 (GLOBE NEWSWIRE) -- Vascular endothelial Growth factor, also known as VEGF, is a naturally occurring protein in the human body responsible for…
Brolucizumab Prevails in Treat-and-Extend Trial of Anti-VEGF Therapy for Eye Disease
NEW YORK CITY -- The monoclonal antibody brolucizumab (Beovu) significantly extended the treatment-free interval without disease…
Larger Choroidal Neovascular Area Predicts Vision Loss Despite Anti-VEGF Therapy
The likelihood of vision loss at 3 months or 1 year despite anti-VEGF therapy increased…
Continuous-Release Anti-VEGF Device for AMD Wins FDA Approval
The FDA has approved a first-of-its kind continuous delivery system for anti-VEGF therapy for…
Continuous-Release Anti-VEGF for Macular Degeneration Continues to Impress
SAN ANTONIO -- An ocular implant that provided 6 months of continuous-release anti-VEGF therapy achieved vision and anatomic…
Bispecific Antibody Compares Favorably With Anti-VEGF for Retinal Disease
SAN ANTONIO -- The bispecific antibody faricimab performed at least as well as standard anti-VEGF therapy for age-related macular…